Low-Dose Naltrexone (LDN) is quickly becoming the preferred treatment for a wide range of Auto-Immune and Chronic Diseases including MS, Crohn's, IBS, Colitis, Cancer, Autism, Rheumatoid Arthritis, ME/CFS, Fibromyalgia, Chronic Pain, Mental Health and more. Here is your opportunity to establish your company as a key player in the worldwide LDN community and take advantage of the growing momentum behind its efficacy.

The LDN AIIC 2020 Conferences are the only LDN focused event in the world. Here, the world’s leading experts and practitioners discuss the latest findings, experiences and case studies while suppliers and providers showcase their latest products and services.

The goal of the conference is to raise awareness of LDN among healthcare professionals and encourage its use in treating a growing number of chronic diseases by highlighting compelling examples and real-world results. We expect 125 onsite attendees and we will record the presentations.


Barbados 2020 Schedule


Discounted Rooms



Get in touch

Leave a message

Use this text to include important information that you'd like your customers to be aware of when contacting you. You could include shop hours, email response times, other ways to contact you, or just some friendly text to encourage your customers to reach out.

Subscribe to the LDN Mailing List

* indicates required
Select a Mailing List - you must be 16+ *

LDN Research Trust will use the information you provide on this form to enable us to email you to provide, newsletters, events, announcements and marketing materials. Please tick the email boxes below.

You can change your mind at any time by clicking the unsubscribe link in the footer of any email you receive from us, or by contacting us at contact@ldnresearchtrust.org. We will treat your information with respect. For more information about our privacy practices please visit our website. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.